Skip to content

Study · Randomized controlled trial · n = 14 · 2013

1 result

Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder.

Domes G, Heinrichs M, Kumbier E, Grossmann A, Hauenstein K, Herpertz SC

Biological psychiatry16 Mar 2013Cited by 185 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialMechanism

    In adults with Asperger syndrome, a single intranasal dose of oxytocin increased right amygdala activity to facial stimuli in a placebo-controlled crossover design.

    In plain wordsIn adults with Asperger syndrome, one dose of oxytocin raised right amygdala brain activity to faces, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseRight amygdala activity to facial stimuli in adults with Asperger syndrome
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    24 IU single dose · intranasalAs given in this study (human).

    Source sentences

    Summary
    After oxytocin treatment, right amygdala activity to facial stimuli increased in the AS group.
    2 context sentences
    Summary · context
    A group of 14 individuals with AS and a group of 14 neurotypical control participants performed a face-matching and a house-matching task during functional magnetic resonance imaging.
    Summary · context
    The effects of a single dose of 24 IU intranasally administered oxytocin were tested in a randomized, placebo-controlled, within-subject, cross-over design.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.